Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the company’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $13.65, for a total transaction of $22,317.75. Following the transaction, the insider owned 8,617 shares in the company, valued at approximately $117,622.05. The trade was a 15.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Scott Bizily also recently made the following trade(s):

• On Tuesday, September 1st, Scott Bizily sold 584 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $14.00, for a total transaction of $8,176.00.
• On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total transaction of $19,620.00.
• On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.20, for a total transaction of $19,947.00.

4D Molecular Therapeutics Trading Up 4.2%

NASDAQ FDMT traded up $0.64 during trading hours on Tuesday, hitting $15.88. The company’s stock had a trading volume of 936,611 shares, compared to its average volume of 831,720. 4D Molecular Therapeutics, Inc. has a twelve month low of $6.96 and a twelve month high of $16.93. The firm has a market capitalization of $877.21 million, a P/E ratio of -6.04 and a beta of 2.74. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05. The stock has a fifty day moving average of $12.87 and a 200 day moving average of $10.90.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The business had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. Equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. The Goldman Sachs Group restated a “buy” rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. B. Riley Financial reiterated a “buy” rating on shares of 4D Molecular Therapeutics in a research report on Monday, August 17th. Chardan Capital raised shares of 4D Molecular Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. Finally, Cantor Fitzgerald upgraded shares of 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price target for the company in a report on Monday, September 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, 4D Molecular Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $28.56.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of large investors have recently bought and sold shares of the company. Jupiter Topco LLC bought a new position in shares of 4D Molecular Therapeutics in the 2nd quarter valued at about $76,466,000. BlackRock Inc. bought a new stake in 4D Molecular Therapeutics during the second quarter worth about $60,463,000. Trails Edge Capital Partners LP acquired a new position in 4D Molecular Therapeutics during the second quarter valued at approximately $29,631,296. Bank of America Corp DE acquired a new position in 4D Molecular Therapeutics during the second quarter valued at approximately $14,905,000. Finally, Evergreen Quality Fund GP Ltd. bought a new position in 4D Molecular Therapeutics in the fourth quarter valued at approximately $7,136,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.

Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.